Marksans Pharma Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹840.80 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1.79 per cent from ₹856.11 crore. This corresponds to a year-on-year *(YoY) growth of 35.62 per cent.
Operating Profit
Operating Profit stands at ₹213.04 crore, reflecting a quarter-on-quarter *(QoQ) increase of 9.02 per cent from ₹195.42 crore. This corresponds to a year-on-year *(YoY) growth of 112.78 per cent.
PBDT
PBDT stands at ₹231.43 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.18 per cent from ₹224.29 crore. This corresponds to a year-on-year *(YoY) growth of 132.13 per cent.
Profit Before Tax
Profit Before Tax stands at ₹206.57 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.29 per cent from ₹200.00 crore. This corresponds to a year-on-year *(YoY) growth of 169.67 per cent.
Net Profit
Net Profit stands at ₹159.41 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.97 per cent from ₹149.03 crore. This represents a 173.90 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Marksans Pharma Ltd Earnings
- YOY
- QOQ
Marksans Pharma Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Marksans Pharma Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Marksans Pharma Ltd Financial Reports
Marksans Pharma Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Marksans Pharma | 0.38% | 3.48% | 1.98% | 15.67% | 78.09% | 76.27% |
| Jubilant Pharmo | -1.05% | 0.94% | -6.79% | -8.40% | 3.91% | -12.47% |
| Astrazeneca Phar | -0.09% | 3.11% | -12.13% | -28.60% | -31.35% | -35.92% |
| Concord Biotech | 1.04% | 4.39% | -5.65% | 3.50% | 33.33% | -7.95% |
| Corona Remedies | 1.03% | 2.79% | -8.06% | -1.04% | 29.80% | 42.15% |
| Akums Drugs | -1.60% | -3.43% | -0.67% | 9.79% | 39.16% | 63.86% |
| Viyash Scientific | -0.38% | -0.81% | -5.28% | -16.48% | 11.42% | 9.80% |
Company Info
Company Information
CMD & Executive Director : Mark Saldanha
Whole Time Executive Director : Sandra Saldanha
Non Independent Executive Director / WTD : Varddhman Vikramaditya Jain
Independent Non Exe. Director : Digant Mahesh Parikh
Independent Non Exe. Director : Abhinna Sundar Mohanty
Non-Exec & Non-Independent Dir : Sunny Sharma
Independent Non Exe. Director : Shailaja Vardhan
Independent Non Exe. Director : Srinivas Mishra
Company Sec. & Compli. Officer : HARSHAVARDHAN PANIGRAHI